Slingshot members are tracking this event:

Novartis (NVS) stops development of fevipiprant LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Clinical Data The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate -to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg). The studies included patients who had inadequately controlled moderate-to-severe asthma (GINA Steps 4 and 5) despite receiving inhaled mid-to-high dose corticosteroids (ICS) and at least one additional controller. The totality of these results do not support further development of fevipiprant in asthma.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 16, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fevipiprant, Dp2 Antagonist, Lung Function, Asthma